Health trends among drug users attending needle exchange programmes in Switzerland (1994-2000)

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 18, Issue 4, 2006, Pages 371-375

  Benninghoff, F ^a   Morency, P ^a   Geense, R ^a   Huissoud, T ^a   Dubois Arber, F ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DRUG ABUSE; DRUG USE; EPIDEMIC; FEMALE; HEALTH BEHAVIOR; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH STATUS; HEALTH SURVEY; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SWITZERLAND;

ADULT; ATTITUDE TO HEALTH; CONDOMS; FEMALE; HEALTH STATUS; HUMANS; MALE; METHADONE; NARCOTICS; NEEDLE-EXCHANGE PROGRAMS; PROSTITUTION; SUBSTANCE ABUSE, INTRAVENOUS; SWITZERLAND;

EID: 33646905728     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120500429018     Document Type: Article

References (50)

1. Benninghoff, F., Gervasoni, J.P., Spencer, B., & Dubois-Arber, F. (1998). Caractéristiques de la clientèle des structures à bas seuil mettant à disposition du matériel d'injection stérile en Suisse. Revue d'Epidémiologie et de Santé Publique, 46, 205-217.
2. Berry, G. (1998). Trends in proportions: ordered groups. In C. Kerr, R. Taylor, & G. Heard (Eds.), Handbook of public health methods. Sidney: McGraw-Hill.
3. Blättler, R., Dobler-Mikola, A., Steffen, T., & Uchtenhagen, A. (2002). Decreasing intravenous cocaine use in opiate users treated with prescribed heroin. Sozial- und Präventivmedizin/ Social and Preventive Medicine/Médecine sociale et préventive, 47, 24-32.
4. Boujon, L., & Beringer, R. (2001). Prise en charge ambulatoire des problèmes de dépendance en 1999: statistique du traitement et de l'assistance ambulatoires dans le domaine de l'alcool et de la drogue. Neuchâtel: Office fédéral de la statistique.
5. Broers, B., Junet, C., Bourquin, M., Deglon, J.J., Perrin, L., & Hirschel, B. (1998). Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS, 12(15), 2059-2066.
6. Centre D'Estudis Epidemiològics Sobre L'hiv/Sida de Catalunya (CEESCAT). (2002). J. Casabona (Ed.), SIVES 2001: Integrated HIV/AIDS surveillance system of Catalonia. Barcelona: Departament de sanitat i seguretat social. (Technical document no. 14).
7. De Preux, E., Dubois-Arber, F., & Zobel, F. (2004). Current trends in illegal drug use and drug related health problems in Switzerland. Swiss Medical Weekly, 134, 313-321.
8. Diaz, T., Des Jarlais, D.C., Vlahov, D., Perlis, T.E., Edwards, V., Friedman, S.R., Rockwell, R., Hoover, D., Williams, I.T., & Monterroso, E.R. (2001). Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. American Journal of Public Health, 91(1), 23-30.
9. Dore, G.J., Law, M., Macdonald, M., & Kaldor, J.M. (2003). Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 26(2), 171-184.
10. Dubois-Arber, F., Jeannin, A., & Spencer, B. (1999). Long term global evaluation of a national AIDS prevention strategy: the case of Switzerland. AIDS, 13, 2571-2582.
11. Dubois-Arber, F., Konings, E., Koffi-Blanchard, M., Gervasoni, J.P., & Hausser, D. (1995). Evaluating HIV prevention of low-threshold needle exchange programmes in Switzerland. In D. Friedrich, & W. Heckmann (Eds.), AIDS in Europe: the behavioural aspect. Report of the Conference AIDS in Europe, the behavioural aspect, Berlin 26-69.9.1994 (pp. 183-90). Berlin: Sigma.
12. Gebhardt, M. (2002). Sida et VIH en Suisse: situation épidémiologique à fin 2001. Berne: Office féderal de la santé publique (OFSP).
13. Gervasoni, J.P., Dubois-Arber, F., Benninghoff, F., Spencer, B., Devos, T., & Paccaud, F. (1996). Evaluation of the Confederation's measures to reduce drug-related problems: second synthesis report 1990-1996. Lausanne: Institut universitaire de médecine sociale et préventive. (Abridged version).
14. Gervasoni, J.P., Zobel, F., Kellerhals, C., Dubois-Arber, F., Spencer, B., Jeannin, A., Benninghoff, F., & Paccaud, F. (2000). Evaluation of the Confederation's measures to reduce drug-related problems: third synthesis report 1997-1999. Lausanne: Institut universitaire de médecine sociale et préventive.
15. Gossop, M., Griffiths, P., Powis, B., Williamson, S., Fountain, J., & Strang, J. (1997). Continuing drug risk behaviour: shared use of injecting paraphernalia among London heroin injectors. AIDS Care, 9(6), 651-660.
16. Hagan, H., Thiede, H., Weiss, N.S., Hopkins, S.G., Duchin, J.S., & Alexander, E.R. (2001). Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health, 91(1), 42-46.
17. Hahn, J.A., Page-Shafer, K., Lum, P.J., Bourgois, P., Stein, E., Evans, J.L., Busch, M.P., Tobler, L.H., Phelps, B., & Moss, A.R. (2002). Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Journal of Infectious Diseases, 186(11), 1558-1564.
18. Hamers, F., & Downs, A.M. (2003). HIV in central and eastern Europe. The Lancet, 361(9362), 1035.
19. Hope, V.D., Judd, A., Hickman, M., Lamagni, T., Hunter, G., Stimson, G.V., Jones, S., Donovan, L., Parry, J.V., & Gill, O.N. (2001). Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? American Journal of Public Health, 91(1), 38-42.
20. Howe, C.J., Fuller, C.M., Ompad, D.C., Galea, S., Koblin, B., Thomas, D., & Vlahov, D (2005). Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug and Alcohol Dependence, 79, 389-395.
21. Kübler, D., & Hausser, D. (1996). Consommateurs d'héroïne et/ou de cocaïne hors traitement médical: étude exploratoire auprès d'une population cachée. Lausanne: Institut universitaire de médecine sociale et préventive. (Cah Rech Doc IUMSP, no. 111.7).
22. Ladewig, D. (2001). A reduction in HIV positive and an increase in hepatitis C positive subjects in methadone maintenance treatments. Swiss Medical Weekly, 131, 422.
23. Langendam, M.W., Van Brussel, G.H., Coutinho, R.A., & Van Ameijden, E.J. (2001). The impact of harm-reduction-based methadone treatment on mortality among heroin users. American Journal of Public Health, 91(5), 774-780.
24. Longshore, D., Bluthenthal, R.N., & Stein, M.D. (2001). Needle exchange program attendance and injection risk in Providence, Rhode Island. AIDS Education and Prevention, 13(1), 78-90.
25. Loxley, W., Bevan, J., & Carruthers, S. (1998). Sex, gender, drugs and risk: the Australian study of HIV and injecting drug use. The International Journal of Drug Policy, 9(4), 255-262.
26. Matheï, C., Buntinx, F., & Van Damme, P. (2002). Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. Journal of Viral Hepatitis, 9, 157-173.
27. Miller, M., Mella, I., Moi, H., & Eskild, A. (2003). HIV and Hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway. Journal of acquired immune deficiency syndromes, 33, 373-379.
28. Murray, J.M., Law, M.G., Gao, Z., & Kaldor, J.M. (2003). The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. International Journal of Epidemiology, 32, 708-714.
29. Myers, T., Cockerill, R., Millson, P., Rankin, J., & Worthington, C. (1995). Les pharmacies communautaires canadiennes, la prévention du VIH/sida et la promotion de la santé: résultats d'une enquête nationale. Ottawa: Glaxo.
30. Nydegger, B., Schumacher, C., & Meier Kressig, M. (1996). Gesamtevaluation der niedrigschwelligen Drogenhilfe in der Stadt Zürich. Zurich: Institut für Suchtforschung (ISF).
31. Observatoire Européen des Drogues et des Toxicomanies (OEDT). (2001). Rapport annuel sur l'état du phénomène de la drogue dans l'Union européenne, 2001. Luxembourg: Office des publications officielles des Communautés européennes.
32. Quaglio, G.L., Lugoboni, F., Pajusco, B., Sarti, M., Talamini, P., & des Jarlais, D.C. (2003). Hepatitis C infection: prevalence, predictor variables and prevention opportunities among drug users in Italy. Journal of Viral Hepatitis, 10(5), 394-400.
33. Rhodes, T., Davis, M., & Judd, A. (2004). Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Addiction, 99, 621-633.
34. Rhodes, T., Donoghoe, M., Hunter, G., Soteri, A., & Stimson, G.V. (1994). Sexual behaviour of drug injectors in London: implications for HIV transmission and HIV prevention. Addiction, 89, 1085-1096.
35. Rhodes, T., Lowndes, C., Judd, A., Mikhailova, L.A., Sarang, A., Rylkov, A., Tichonov, M., Lewis, K., Ulyanova, N., Alpatova, T., Karavashkin, V., Khutorskoy, M., Hickman, M., Parry, J.V., & Renton, A. (2002). Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS, 16(13), F25-F31.
36. Ronco, C., Spuhler, G., Coda, P., & Schöpfer, R. (1996). Evaluation der Gassenzimmer I, II und III in Basel. Sozial-und Präventivmedizin/Social and Preventive Medicine/Médecine sociale et préventive, 41(S1), S58-S68.
37. Roy, K., Hay, G., Andragetti, R., Taylor, A., Goldberg, D., & Wiessing, L. (2002). Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiology and Infection, 129(3), 577-585.
38. Sabbatini, A., Carulli, B., Villa, M., Correa Leite, M.L., & Nicolosi, A. (2001). Recent trends in the HIV epidemic among injecting drug users in Northern Italy, 1993-1999. AIDS, 15(16), 2181-2185.
39. Scheitlin, T., Joller-Jemelka, H.I., & Grob, P.J. (1992). Hepatitis und HIV-Infektionen bei Benützern une Benützerinnen illegaler Drogen. Schweizerische Medizinische Wochenschrift, 122, 1432-1445.
40. Somaini, B., Wang, J., Perozo, M., Kuhn, F., Meili, D., Grob, P., & Flepp, M. (2000). A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care, 12(4), 449-460.
41. Strathdee, S.A., Patrick, D.M., Currie, S.L., Cornelisse, P.G., Rekart, M.L., Montaner, J.S., Schechter, M.T., & O'Shaughnessy, M.V. (1997). Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS, 11(8), F59-F65.
42. Thorpe, L., Ouellet, L.J., Hershow, R., Bailey, S.L., Williams, I.T., Williamson, J., Monterroso, E.R., & Garfein, R.S. (2002). Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology, 155(7), 645-653.
43. Uchtenhagen, A. (1995). Harm reduction: the case of Switzerland. European Addiction Research, 1, 86-91.
44. Uchtenhagen, A., Dobler-Mikola, A., & Gutzwiller, F. (1996). Medically controlled prescription of narcotics: A Swiss national project. The International Journal of Drug Policy, 7(1), 28-33.
45. UNAIDS/WHO - Working Group on Global HIV/AIDS And STI Surveillance. (2000). Guidelines for Second generation HIV Surveillance. Geneva: UNAIDS/WHO - Working Group on Global HIV/AIDS and STI Surveillance.
46. Valenciano, M., Emmanuelli, J., & Lert, F. (2001). Unsafe injecting practices among attenders of syringe exchange programmes in France. Addiction, 96(4), 597-606.
47. Van Ameijden, E.J.C., & Coutinho, R.A. (1998). Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS, 12(6), 669-670.
48. Van Ameijden, E.J.C., Van Den Hoek, J.A.R., & Coutinho, R.A. (1994). Injecting risk behavior among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. American Journal of Public Health, 84(2), 275-281.
49. Wang, J., Rey-Riek, S., Steffen, T., Rehm, J., & Somaini, B. (2001). Drogenszenestudie Zürich 2000. Zurich: Institut für Suchtforschung; Institut für Sozial- und Präventivmedizin der Universität Zürich.
50. Zobel, F., Thomas, R., Arnaud, S., de Preux, E., Ramstein, T., Spencer, B., Jeannin, A., Dubois-Arber, F., Kellerhals, C., Morency, P., So-Barazetti, B., Ernst, M.L., Benninghoff, F., & Gervasoni, J.P. (2003). Evaluation of the Confederation's measures to reduce drug-related problems: fourth synthesis report 1999-2002. Lausanne: Institut universitaire de médecine sociale et préventive.